Current Status of COVID-19 Outbreak and Vaccination in the Republic of Korea

Health
By. Myoungryu Kim, Jueun Kwon, Boksil Hong Views. 2003

Abstract

Purpose: This study examines the current status of COVID-19 vaccination in the Republic of Korea. Therefore, we investigate the currently approved COVID-19 vaccines and their properties, COVID-19 vaccine prioritization guidance and timeline, and the status of adverse events after the COVID-19 vaccination. Moreover, we examine the SARS-CoV-2 variants and the current prevalent variants in the Republic of Korea.

Method: This study was conducted on Web-based searches about the latest updates COVID-19 from the World Health Organization, Korea Centers for Disease Control and Prevention, and the Ministry of Food and Drug Safety. In addition, we searched for the “COVID-19 OR vaccines” in PubMed and then reviewed the selected articles regarding COVID-19 vaccines, prioritization guidance, adverse effects, and variants.

Results: To date, 4 COVID-19 vaccines have been received regulatory approval in the Republic of Korea. To promote stable COVID-19 vaccination, the COVID-19 Vaccination Promotion Task Force announced the order of COVID-19 vaccine distribution and vaccination schedules from the first and the third quarter of 2021, intending to complete the first dose of vaccination in 70% of the country's population by the end of September 2021. Currently, a total of 20,169,592 vaccine doses have been administered until August 02, 2021, representing 38.9% of the total population, and 7,289,659 individuals(about 14.1% of the country’s population) have been fully vaccinated so far. In total, 0.49%(105,937 cases) of individuals who were vaccinated reported adverse effects. Among them, 94.9% were general adverse reactions, and 5.1% were severe adverse effects, including death and suspected anaphylaxis(severe allergic reactions). Recently, Delta variant is significantly expanding since June, and it is currently the predominant strain of the virus in the Republic of Korea.

Conclusion: Since June 12, the highest Social Distancing Level 4 has been implemented in the Seoul Metropolitan Area. With COVID-19 vaccination, we need to cooperate with antivirus measures and cancel unnecessary social gatherings to protect ourselves from the persistent infectious disease.

[Keywords] Approved COVID-19 Vaccines, COVID-19 Vaccine Prioritization, COVID-19 Vaccination Schedules, Adverse Reactions, SARS-CoV-2 Variants



References

[4] Park IN & Yum HK. Stepwise Strategy of Social Distancing in Korea. Journal of Korean Medical Science, 35(28), 1-6 (2020).
[5] Park G & Lee W & Lim Y. Covid-19 and Some Implications to AI. Robotics & AI Ethics, 5(1), 16-24 (2020). [Article]
[6] Kim D. Government Roles of Policy Networks against Covid-19: Comparing Two Cases in S. Korea. Protection Convergence, 5(2), 14-26 (2020). [Article]
[7] Cho H & Park S & Lim Y. Human Security Task and Prospect on Covid-19 Pandemic. International Journal of Terrorism & National Security, 5(2), 48-55 (2020). [Article]
[8] Park G & Kim H & Li Y. Virtue for Post Covid-19 and AI Technology. Robotics & AI Ethics, 5(2), 8-18 (2020). [Article]
[9] Lee S. Paradox of Covid-19 Pandemic Strengthening Neo-liberalist’s Way of Global Governance Building to Overcome Vaccine Nationalism's Politics. Regulations, 6(2), 1-9 (2021). [Article]
[10] Carvalho T & Krammer F & Iwasaki A. The First 12 Months of Covid-19: A Timeline of Immunological Insights. Nature Reviews Immunology, 21, 245-256 (2021).
[11] Xia S & Zhu Y & Liu M & Lan Q & Xu W & Wu Y & Ying T & Lu S & Shi Z & Jiang S & Lu L. Fusion Mechanism of 2019-nCoV and Fusion Inhibitors Targeting HR1 Domain in Spike Protein. Cellular & Molecular Immunolgy, 17, 765-767 (2020).
[12] Angeli F & Spanevello A & Reboldi G & Visca D & Verdecchia P. SARS-CoV-2 Vaccines: Lights and Shadows. European Journal of Internal Medicine, 88, 1-8 (2021).
[16] Voysey M & Clemens SAC & Madhi SA & Weckx L & Folegatti PM & Aley PK & Angus B & Baillie VL & Barnabas SL & Bhorat QE & Bibi S & Briner C & Ciconi P & Collins AM & Colin-Jones R & Cutland CL & Darton TC & Dheda K & Duncan CHA & Emary KRW & Ewer KJ & Fairle L & Faust SN & Feng & Ferreira DM & Finn A & Goodman AL & Green CM & Green CA & Heath PT & Hill C & Hill H & Hirshe I & Hodgson SHC & Izu A & Jackson S & Jenkin D & Joe CCD & Kerridge S & Koean A & Kwatra G & Lazarus R & Lawrie AM & Lelliott A & Libri V & Lillie PJ & Mallory R & Mendes AVA & Milan EP & Minassian AM & McGregor A & Morrison H & Mujadidi YF & Nana A & O’Reilly PJ & Padayachee SD & Pittella A & Plested E & Pollock KM & Ramasamy MN & Rhead S & Schwarzbold AV & Singh N & Smitn A & Song R & Snape D & Sprinz E & Sutherland RK & Tarrant R & Thomson EC & ToroK ME & Toshner M & Turner DPJ & Vekemans J & Vilafana TL & Watson MEE & Williams CJ & Douglas AD & Hill AVS & Lambe T & Gilbert SC & Pollard AJ & Oxford Covid Vaccine Trial Group. Safety and Efficacy of the ChAdOx1 nCoV-19 Vaccine(AZD1222) against SARS-CoV-2: An Interim Analysis of Four Randomised Controlled Trials in Brazil, South Africa, and the UK. Lancet, 397, 99-111 (2021).
[23] Noh EB & Nam HK &Lee H. Which Group Should be Vaccinated First?: A Systematic Review. Infection & Chemotherapy, 53, 261-270 (2021).
[24] Turner PJ & Ansotegui IJ & Campbell DE & Cardona V & Ebisawa M & EI-Gamal Y & Fineman S & Geller M & Gonzalez-Estrada A & Greenberger PA & Leung ASY & Levin ME & Muraro A & Borges MS & Senna G & Tanno LK & Thong BY & Worm M & WAO Anaphylais Commuittee. Covid-19 Vaccine-associated Anaphylaxis: A Statement of the World Allergy Organization Anaphylaxis Committee. World Allergy Organ Journal, 14, 100517 (2021).
[25] Stone CA & Rukasin CRF & Beachkofsky TM & Phillips EJ. Immune-mediated Adverse Reactions to Vaccines. British Journal of Clinical Pharmacology, 85, 2694-2706 (2019).
[26] Kim MA & Lee YW & Kim SR Kim JH & Kim TK & Park HS & Shin M & Ye YM & Lee S & Lee J & Choi JH & Jang GC & Chang YS. Covid-19 Vaccine-associated Anaphylaxis and Allergic Reactions: Consensus Statements of the KAAACI Urticaria/Angioedema/Anaphylaxis Working Group. Allergy, Asthma & Immunology Research, 13, 525-544 (2021).
[27] Pormohammad A & Zarei M & Ghorbani S & Mohammadi M & Razizadeh MH & Turner DL & Turner RJ. Efficacy and Safety of Covid-19 Vaccines: A Systematic Review and Meta-analysis of Randomized Clinical Trials. Vaccines(Basel), 9(5), 467-467 (2021).
[28] Oh H & Lee Y & Kim T & Lee E & Park S. Status of Adverse Reactions after Covid-19 Vaccination in the Republic of Korea. Public Health Weekly Report, 14(19), 1092-1098 (2021).
[29] Shaw RH & Stuart A & Greenland M & Liui X & Van-Tam JSN & Snape MD & Com-CoV Study Group. Heterologous Prime-boost Covid-19 Vaccination: Initial Reactogenicity Data. Lancet, 397, 2043-2049 (2021).
[30] Lewis D. Mix-and-match Covid Vaccines: The Case is Growing, but Questions Remain. Nautre, 595, 344-345 (2021).
[31] Gupta RK. Will SARS-CoV-2 Variants of Concern Affect the Promise of Vaccines?. Nature Reviews Immunology, 21, 340-341 (2021).
[33] Rambaut A & Holmes EC & O'Toole A & Hill V & McCrone JT & Ruis C & Plessis L & Pybus OG. A Dynamic Nomenclature Proposal for SARS-CoV-2 Lineages to Assist Genomic Epidemiology. Nature Microbiology, 5, 1403-1407 (2001).
[36] Sheikh A & McMenamin J & Taylor B & Robertson C & Public Health Scotland and the EAVE II Collaborators. SARS-CoV-2 Delta VOC in Scotland: Demographics, Risk of Hospital Admission, and Vaccine Effectiveness. Lancet, 397, 2461-2462 (2021).
[38] Krause PR & Fleming TR & Longini IM & Peto R & Briand S & Heymann DL & Beral V & Snape MD & Rees H & Ropero A & Baicer RD & Cramer JP & Munoz-Fontela C & Gruber M & Gaspar R & Singh J & Subbarao K & Kerkhove MDV & Swaminathan S & Ryan MJ & Henao-Restrepo A. SARS-CoV-2 Variants and Vaccines. New England Journal of Medicine, 385, 179-186 (2021).
[40] Zhou W & Wan W. Fast-spreading SARS-CoV-2 Variants: Challenges to and New Design Strategies of COVID-19 Vaccines. Signal Transduction and Targeted Therapy, 6, 226-226 (2021).
[41] Li Q & Wang J & Tang Y & Lu H. Next-generation Covid-19 Vaccines: Opportunities for Vaccine Development and Challeges in Tackling Covid-19. Drug Discoveries & Therapeutics, 15(3), 118-123 (2021).



[1] https://www.who.int/ (2020).
[2] https://covid19.who.int/ (2021).
[3] http://ncov.mohw.go.kr/ (2021).
[13] http://mfds.go.kr/ (2021).
[14] https://www.pfizer.com/ (2021).
[15] https://investeors.modernatx.com/ (2021).
[17] https://www.jnj.com/ (2021).
[18] https://www.who.int/ (2020).
[19] WHO SAGE Values Framework for the Allocation and Prioritization of COVID-19 Vaccination (2020).
[20] https://www.gov.uk/ (2020).
[21] https://www.cdc.gov/ (2021).
[22] https://ncv.kdca.go.kr/ (2021).
[32] https://bbc.com/ (2021).
[34] https://gisaid.org/ (2021).
[35] https://www.neca.re.kr/ (2021).
[37] Nasreen S & Chung H & He S & Brow KA & Gubbay JB & Buchan SA & Fel DB & Austin PC & Schwartz KL & Sundaram ME & Galzavara A & Chen B & Tadrous M & Wilson K & Wilson SE & Kwong JC. Effectiveness of COVID-19 Vaccines against Variants of Concern in Ontario, Canata. MedRxiv (2021).
[39] https://news.un.org/ (2021).



? Source: edaily.co.kr